Secretoneurin as a marker for hypoxic brain injury after cardiopulmonary resuscitation

Haßlacher, Julia; Lehner, Georg; Harler, Ulrich; Beer, Ronny; Ulmer, Hanno; Kirchmair, Rudolf; Fischer‐Colbrie, Reiner; Bellmann, Romuald; Dunzendorfer, Stefan; Joannidis, Michael

doi:10.1007/s00134-014-3423-4

Cited by 38 publications

(36 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most striking finding was that secretoneurin serum concentrations were significantly higher in neonates with HIE than in healthy term neonates. Our findings are in accordance with those of Shyu et al [13], who reported increased secretoneurin serum concentrations in 20 adult stroke patients, and a study by Hasslacher et al [14], who showed in 134 patients that secretoneurin is elevated after cardiopulmonary resuscitation. At present, it cannot be ruled out that elevations in secretoneurin levels reflect the severity of asphyxia.…”

Section: Discussionsupporting

confidence: 83%

“…At present we still lack a biomarker that could early identify infants at risk for brain injury, especially those with mild or moderate HIE. It is important to note that secretoneurin is not influenced by hypothermia [14]. Secretoneurin might have the potential to be a diagnostic biomarker.…”

Section: Discussionmentioning

confidence: 99%

“…Elevated secretoneurin concentrations have been detected in adults suffering from brain injury after cardiopulmonary resuscitation. Notably, secretoneurin was a prognostic biomarker for poor neurologic outcome in these patients [14]. So far, no data are available concerning secretoneurin in neonates.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Secretoneurin Serum Levels in Healthy Term Neonates and Neonates with Hypoxic-Ischaemic Encephalopathy

Wechselberger

Schmid²,

Posod³

et al. 2016

Neonatology

Self Cite

View full text Add to dashboard Cite

Background: Hypoxic-ischaemic encephalopathy is a major cause of neurologic impairment and mortality in neonates. Early knowledge of brain injury is important to guide therapeutic decisions and reliably inform the parents. Increased secretoneurin levels have been detected in adult patients suffering from brain injury and it has also been shown to be a promising early serum biomarker of unfavourable neurological outcome. However, no data are available in neonates. Objective: The aim of this study was to obtain reference values for secretoneurin in healthy term neonates and then to assess the potential of this neuropeptide as a biomarker in the context of hypoxic-ischaemic encephalopathy in asphyxiated term neonates. Methods: A total number of 139 term neonates, of which 7 were asphyxiated and 132 were healthy, were prospectively enrolled. Secretoneurin serum concentrations were assessed by radioimmunoassay. Results: In healthy controls, secretoneurin serum concentrations were influenced by the mode of delivery (highest in infants born per vacuum extraction and lowest in infants born per caesarean section) and abnormal cardiotocography. In asphyxiated term neonates, secretoneurin concentrations were higher in umbilical cord blood and significantly lower 48 h after birth in comparison to healthy controls. Conclusion: Secretoneurin levels are elevated in cord blood in infants suffering from hypoxic-ischaemic encephalopathy following perinatal asphyxia. The potential of secretoneurin as a marker of neonatal hypoxic-ischaemic brain injury should be further evaluated in larger trials.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Secretoneurin Serum Levels in Healthy Term Neonates and Neonates with Hypoxic-Ischaemic Encephalopathy

Wechselberger

Schmid²,

Posod³

et al. 2016

Neonatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In patients with acute heart failure and after ventricular arrhythmia-induced cardiac arrest, secretoneurin provided additional prognostic information to clinical variables and norepinephrine, NT-proBNP, and hs-TnT levels. Other groups have also found secretoneurin to predict outcome after cardiac arrest (10). In contrast, admission secretoneurin levels were not associated with outcome in patients with acute exacerbations of chronic obstructive pulmonary disease (9), although these patients had comparable severity of dyspnea and mortality rates as the acute heart failure patients.…”

mentioning

confidence: 86%

“…1) (13). Four hundred seventy patients were included, and blood samples were available from 232 patients at ICU admission (median, 9 [Q1-Q3, [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17] hr from study inclusion to sampling) and from 201 patients after 72 hours.…”

Section: Methodsmentioning

confidence: 99%

Prognostic Value of Secretoneurin in Critically Ill Patients With Infections

Røsjø

Stridsberg

Ottesen

et al. 2016

Critical Care Medicine

View full text Add to dashboard Cite

1Objectives : Secretoneurin is produced in neuroendocrine cells, and the myocardium and circulating secretoneurin levels provide incremental prognostic information to established risk indices in cardiovascular disease. As myocardial dysfunction contributes to poor outcome in critically ill patients, we wanted to assess the prognostic value of secretoneurin in two cohorts of critically ill patients with infections. Design: Two prospective, observational studies. Setting: Twenty-four and twenty-five ICUs in Finland. Patients: A total of 232 patients with severe sepsis (cohort #1) and 94 patients with infections and respiratory failure (cohort #2). Interventions: None. Measurements and Main Results: We measured secretoneurin levels by radioimmunoassay in samples obtained early after ICU admission and compared secretoneurin with other risk indices. In patients with severe sepsis, admission secretoneurin levels (logarithmically transformed) were associated with hospital mortality (odds ratio, 3.17 [95% CI, 1.12-9.00]; p = 0.030) and shock during the hospitalization (odds ratio, 2.17 [1.06-4.46]; p = 0.034) in analyses that adjusted for other risk factors available on ICU admission. Adding secretoneurin levels to age, which was also associated with hospital mortality in the multivariate model, improved the risk prediction as assessed by the category-free net reclassification index: 0.35 (95% CI, 0.06-0.64) (p = 0.02). In contrast, N-terminal pro-B-type natriuretic peptide levels were not associated with mortality in the multivariate model that included secretoneurin measurements, and N-terminal pro-B-type natriuretic peptide did not improve patient classification on top of age. Secretoneurin levels were also associated with hospital mortality after adjusting for other risk factors and improved patient classification in cohort #2. In both cohorts, the optimal cutoff for secretoneurin levels at ICU admission to predict hospital mortality was ≈ 175 pmol/L, and higher levels were associated with mortality also when adjusting for Simplified Acute Physiology Score II and Sequential Organ Failure Assessment scores. Conclusions: Secretoneurin levels provide incremental information to established risk indices for the prediction of mortality and shock in critically ill patients with severe infections. (Crit Care Med 2016; XX:00-00)

show abstract

Secretogranin II: Novel Insights into Expression and Function of the Precursor of the Neuropeptide Secretoneurin

Fischer‐Colbrie

Theurl

Kirchmair

2017

Chromogranins: From Cell Biology to Physiology and Biomedicine

View full text Add to dashboard Cite

Secretoneurin as a marker for hypoxic brain injury after cardiopulmonary resuscitation

Abstract: SN is a promising early biomarker for hypoxic brain injury. Further studies will be required for confirmation of these results.

Cited by 38 publications

References 40 publications

Secretoneurin Serum Levels in Healthy Term Neonates and Neonates with Hypoxic-Ischaemic Encephalopathy

Secretoneurin Serum Levels in Healthy Term Neonates and Neonates with Hypoxic-Ischaemic Encephalopathy

Prognostic Value of Secretoneurin in Critically Ill Patients With Infections

Secretogranin II: Novel Insights into Expression and Function of the Precursor of the Neuropeptide Secretoneurin

Contact Info

Product

Resources

About